A Predictable Worm: Application of Caenorhabditis elegans for Mechanistic Investigation of Movement Disorders

Neurotherapeutics

Volumn 9, Issue 2, 2012, Pages 393-404

  Dexter, Paige M ^a   Caldwell, Kim A ^a,b   Caldwell, Guy A ^a,b  

^a UNIVERSITY OF ALABAMA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Dopamine; Dystonia; Endoplasmic reticulum stress; Neurodegeneration; Parkinson's disease; TorsinA

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALPHA SYNUCLEIN; BAFILOMYCIN; CAENORHABDITIS ELEGANS PROTEIN; DJ 1 PROTEIN; DOPAMINE; GREEN FLUORESCENT PROTEIN; PARACETAMOL; RAB PROTEIN; RNA; TYROSINE 3 MONOOXYGENASE;

BIOASSAY; BIOAVAILABILITY; BIOMECHANICS; CAENORHABDITIS ELEGANS; CELL LINEAGE; CELL VIABILITY; CLINICAL FEATURE; DEFECATION; DEGENERATIVE DISEASE; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DROSOPHILA; DYSTONIA; EGG LAYING; ENDOPLASMIC RETICULUM STRESS; ESCHERICHIA COLI; EVALUATION; GENE IDENTIFICATION; GENE LOCUS; GENETIC CODE; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; HERMAPHRODITISM; HUMAN; LIFESPAN; LOCOMOTION; MICROINJECTION; MOTOR DYSFUNCTION; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE; SEX RATIO; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SUBSTANTIA NIGRA;

ANIMALS; CAENORHABDITIS ELEGANS; CAENORHABDITIS ELEGANS PROTEINS; DISEASE MODELS, ANIMAL; FORECASTING; HUMANS; MOVEMENT DISORDERS; NERVE DEGENERATION;

EID: 84859698344     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-012-0109-x     Document Type: Review

References (75)

1. White JG, Southgate E, Thomson JN, Brenner S. The structure of the nervous system of Caenorhabditis elegans. Philos Trans R Soc Lond 1986; 275: 327-348.
2. Altun ZF, Hall DH. In: WormAtlas available at http://www. wormatlas. org. Accessed September 16, 2011.
3. Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC. Green fluorescent protein as a marker for gene expression. Science 1994; 263: 802-805.
4. Schwarz EM. Genomic classification of protein-coding gene families. In: The C. elegans Research Community, ed. WormBook 2005, doi/10. 1895/wormbook. 1. 29. 1, http://www. wormbook. org.
5. Chalfie M, White J. The nervous system. In: Wood WB, ed. The Nematode Caenorhabditis elegans, Cold Spring Harbor Laboratory Press, Cold Spring Harbor: NY 1988.
6. Bargmann CI. Neurobiology of the C. elegans Genome. Science 1998; 282: 2028-2033.
7. Nass R, Hall DH, Miller DM 3 rd, Blakely RD. Neurotoxin-induced degeneration of converted dopamine neurons in Caenorhabditis elegans. Proc Natl Acad Sci USA 2002; 99: 3264-3269.
8. Braungart E, Gerlach M, Riederer P, Baumeister R, Hoener MC. Caenorhabditis elegans MPP + model of Parkinson's disease for high-throughput drug screenings. Neurodegener Dis 2004; 1: 175-183.
9. Potts MB, Cameron S. Cell lineage and cell death: Caenorhabditis elegans and cancer research. Nat Rev Cancer 2011; 11: 50-58.
10. Richmond J. Synaptic function. In: The C. elegans Research Community, ed., WormBook 2007; doi: 10. 1895/wormbook. 1. 69. 1, http://www. wormbook. org.
11. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-840.
12. Burré J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Südhof TC. α-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 2010; 329: 1663-1667.
13. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011; 146: 37-52.
14. Hamamichi S, Rivas RN, Knight AL, Cao S, Caldwell KA, Caldwell GA. Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model. Proc Natl Acad Sci USA 2008; 105: 728-733.
15. Lakso M, Vartiainen S, Moilanen AM, et al. Dopaminergic neuronal loss and motor defecits in Caenorhabditis elegans overexpressing human alpha-synuclein. J Neurochem 2003; 86: 165-172.
16. Kuwahara T, Koyama A, Gengyo-Ando K, et al. Familial Parkinson mutant alpha-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans. J Biol Chem 2006; 281: 334-340.
17. Karpinar DP, Balija MB, Kügler S, et al. Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. Mol Syst Biol 2009; 28: 3256-3268.
18. Nass R, Miller DM, Blakely RD. C. elegans: a novel pharmacogenetic model to study Parkinson's disease. Parkinsonism Related Disord 2001; 7: 185-191.
19. Sawin ER, Ranganathan R, Horvitz HR. C. elegans locomotory rate is modulated by the environment through a dopaminergic pathway and by experience through a serotonergic pathway. Neuron 2000; 26: 619-631.
20. Vidal-Gadea A, Topper S, Young L, et al. Caenorhabditis elegans selects distinct crawling and swimming gaits via dopamine and serotonin. Proc Natl Acad Sci USA 2011; 108: 17504-17509.
21. Yacoubian TA, Cantuti-Castelvetri I, Bouzou B, et al. Transcriptional dysregulation in a transgenic model of Parkinson disease. Neurobiol Dis 2008; 29: 515-528.
22. Porter GW, Khuri FR, Fu H. Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Semin Cancer Biol 2006; 16: 193-202.
23. Yacoubian TA, Slone SR, Harrington AJ, et al. Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease. Cell Death Dis 1; e2; doi: 10. 1038/cddis. 2009. 4.
24. Cooper AA, Gitler AD, Cashikar A, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006; 313: 324-328.
25. Gitler AD, Bevis BJ, Shorter J, et al. The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci USA 2008; 105: 145-150.
26. Su LJ, Auluck PK, Outeiro TF, et al. Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech 2010; 3: 194-208.
27. Yeger-Lotem E, Riva L, Su LJ, et al. Bridging high-throughput genetic and transcriptional data reveals cellular responses to α-synuclein toxicity. Nat Genet 2009; 41: 316-323.
28. Gitler AD, Chesi A, Geddie ML, et al. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet 2009; 41: 308-315.
29. Ramirez A, Heimbach A, Gründemann J, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006; 38: 1184-1191.
30. Klein C, Lohmann-Hedrich K. Impact on recent genetic findings in Parkinson's disease. Curr Opin Neurol 2007; 20: 453-464.
31. Qiao L, Hamamichi S, Caldwell KA, et al. Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol Brain 2008; 1: 17.
32. Bowers K, Stevens TH. Protein transport from the late Golgi to the vacuole in the yeast Saccharomyces cerevisiae. Biochim Biophys Acta 2005; 1744: 438-454.
33. Ruan Q, Harrington AJ, Caldwell KA, Caldwell GA, Standaert DG. VPS41, a protein involved in lysosomal trafficking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson's disease. Neurobiol Dis 2010; 37: 330-338.
34. Tucci A, Nalls MA, Houlden H, et al. Genetic variability at the PARK16 locus. Eur J Hum Genet 2010; 18: 1356-1359.
35. Brett CL, Plemel RL, Lobinger BT, Vignali M, Fields S, Merz AJ. Efficient termination of vacuolar Rab GTPase signaling requires coordinated action by a GAP and a protein kinase. J Cell Biol 2008; 182: 1141-1151.
36. Fung HC, Scholz S, Matarin M, et al. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol 2006; 5: 911-916.
37. Komatsu M, Waguri S, Chiba T, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006; 441: 880-884.
38. Shacka JJ, Klocke BJ, Shibata M, et al. Bafilomycin A1 inhibits chloroquine-induced death of cerebellar granule neurons. Mol Pharmacol 2006; 69: 1125-1136.
39. Pivtoraiko VN, Harrington AJ, Mader BJ, et al. Low-dose bafilomycin attenuates neuronal cell death associated with autophagy-lysosome pathway dysfunction. J Neurochem 2010; 114: 1193-1204.
40. Cao S, Gelwix CC, Caldwell KA, Caldwell GA. Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. J Neurosci 2005; 25: 3801-3812.
41. Locke CJ, Fox SA, Caldwell GA, Caldwell KA. Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease. Neurosci Lett 2008; 439: 129-133.
42. Yao C, El Khoury R, Wang W, et al. LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease. Neurobiol Dis 2010; 40: 73-81.
43. Liu Z, Hamamichi S, Lee BD, et al. Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Hum Mol Genet 2011; 20: 3933-3942.
44. Lee S, Liu H, Lin W, Guo H, Lu B. LRRK2 Kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the drosophila neuromuscular junction. J Neurosci 2010; 30: 16959-16969.
45. Caldwell KA, Tucci ML, Armagost J, et al. Investigating bacterial sources of toxicity as an environmental contributor to dopaminergic neurodegeneration. PLoS One 2009; 4: e7277.
46. Helmcke KJ, Syversen T, Miller DM 3 rd, Aschner M. Characterization of the effects of methylmercury on Caenorhabditis elegans. Toxicol Appl Pharmacol 2009; 240: 265-272.
47. Jiang GC, Hughes S, Stürzenbaum SR, Evje L, Syversen T, Aschner M. Caenorhabditis elegans metallothioneins protect against toxicity induced by depleted uranium. Toxicol Sci 2009; 111: 345-354.
48. Vanduyn N, Settivari R, Wong G, Nass R. SKN-1/Nrf2 inhibits dopamine neuron degeneration in a Caenorhabditis elegans model of methylmercury toxicity. Toxicol Sci 2010; 118: 613-624.
49. Jadiya P, Khan A, Sammi SR, Kaur S, Mir SS, Nazir A. Anti-Parkinsonian effects of Bacopa monnieri: insights from transgenic and pharmacological Caenorhabditis elegans models of Parkinson's disease. Biochem Biophys Res Commun 2011; 413: 605-610.
50. McColl G, Killilea DW, Hubbard AE, Vantipalli MC, Melov S, Lithgow GJ. Pharmacogenic analysis of lithium-induced delayed aging in Caenorhabditis elegans. J Biol Chem 2007; 283: 350-357.
51. Davies AG, Pierce-Shimomura JT, Kim H, et al. A central role of the BK potassium channel in behavioral responses to ethanol in C. elegans. Cell 2003; 115: 655-666.
52. Evanson K, Huang C, Yamben I, Covey DF, Kornfeld K. Anticonvulsant medications extend worm life-span. Science 2005; 307: 258-262.
53. Burns AR, Wallace IM, Wildenhain J, et al. A predictive model for drug bioaccumulation and bioactivity in Caenorhabditis elegans. Nat Chem Biol 2010; 6: 549-557.
54. Cao S, Hewett JW, Yokoi F, et al. Chemical enhancement of torsinA function in cell and animal models of torsion dystonia. Dis Model Mech 2010; 3: 386-396.
55. Breakefield XO, Blood AJ, Li Y, Hallett M, Hanson PI, Standaert DG. The pathophysiological basis of dystonias. Nat Rev Neurosci 2008; 9: 222-234.
56. Ozelius LJ, Hewett JW, Page CE, et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet 1997; 17: 40-48.
57. Goodchild RE, Dauer WT. Mislocalization to the nuclear envelope: An effect of the dystonia-causing torsinA mutation. Proc Natl Acad Sci USA 2004; 101: 847-852.
58. Naismith TV, Heuser JE, Breakefield XO, Hanson PI. TorsinA in the nuclear envelope. Proc Natl Acad Sci USA 2004; 101: 7612-7617.
59. Torres GE, Sweeney AL, Beaulieu JM, Shashidharan P, Caron MG. Effect of torsinA on membrane proteins reveals a loss of function and a dominant-negative phenotype of the dystonia-associated DeltaE-torsinA mutant. Proc Natl Acad Sci USA 2004; 101: 15650-15655.
60. Nery FC, Zeng J, Niland BP, et al. TorsinA binds the KASH domain of nesprins and participates in linkage between nuclear envelope and cytoskeleton. J Cell Sci 2008; 121: 3476-3486.
61. Neuwald AF, Aravind L, Spouge JL, Koonin EV. AAA+: a class of chaperone-like ATPases associated with the assembly, operation, and disassembly of protein complexes. Genom Res 1999; 9: 27-43.
62. Hanson PI, Whiteheart SW. AAA + proteins: have engine, will work. Nat Rev Mol Cell Biol 2005; 6: 519-529.
63. Basham SE, Rose LS. The Caenorhabditis elegans polarity gene ooc-5 encodes a Torsin-related protein of the AAA ATPase superfamily. Development 2001; 128: 4645-4656.
64. Kustedjo K, Bracey MH, Cravatt BF. TorsinA and its torsion dystonia-associated mutant forms are lumenal glycoproteins that exhibit distinct subcellular localizations. J Biol Chem 2000; 275: 27933-27939.
65. Liu Z, Zolkiewska A, Zolkiewski M. Characterization of human torsinA and its dystonia-associated mutant form. Biochem J 2003; 374: 117-122.
66. Hewett JW, Tannous B, Niland BP, et al. Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cells. Proc Natl Acad Sci USA 2007; 104: 7271-7276.
67. Basham SE, Rose LS. Mutations in ooc-5 and ooc-3 disrupt oocyte formation and the reestablishment of asymmetric PAR protein localization in two-cell Caenorhabditis elegans embryos. Dev Biol 1999; 215: 253-263.
68. Zhu L, Wrabl JO, Hayashi AP, Rose LS, Thomas PJ. The torsin-family AAA + protein OOC-5 contains a critical disulfide adjacent to Sensor-II that couples redox state to nucleotide binding. Mol Biol Cell 2008; 19: 3599-3612.
69. Caldwell GA, Cao S, Sexton EG, Gelwix CC, Bevel JP, Caldwell KA. Suppression of polyglutamine-induced protein aggregation in Caenorhabditis elegans by torsin proteins. Hum Mol Genet 2003; 12: 307-319.
70. Sharma N, Hewett J, Ozelius LJ, et al. A close association of torsinA and alpha-synuclein in Lewy bodies: a fluorescence resonance energy transfer study. Am J Pathol 2001; 159: 339-344.
71. Bressman SB. Dystonia: phenotypes and genotypes. Rev Neurol (Paris) 2003; 159: 849-856.
72. Chen P, Burdette AJ, Porter JC, et al. The early-onset torsion dystonia-associated protein, torsinA, is a homeostatic regulator of endoplasmic reticulum stress response. Hum Mol Genet 2010; 19: 3502-3515.
73. Nery FC, Armata IA, Farley JE, et al. TorsinA participates in endoplasmic reticulum-associated degradation. Nat Commun 2: 393. doi: 10. 1038/ncomms1383.
74. Risch NJ, Bressman SB, Senthil G, Ozelius LJ. Intragenic Cis and Trans modification of genetic susceptibility in DYT1 torsion dystonia. Am J Hum Genet 2007; 80: 1188-1193.
75. Dang MT, Yokoi F, McNaught KS, et al. Generation and characterization of Dyt1 DeltaGAG knock-in mouse as a model for early-onset dystonia. Exp Neurol 2005; 196: 452-463.